Market Size in 2022 | Market Forecast in 2030 | CAGR (in %) | Base Year |
---|---|---|---|
USD 1.23 Billion | USD 5,976.34 Billion | 1.95% | 2022 |
The global aquagenic pruritus treatment market size was worth around USD 1.23 billion in 2022 and is predicted to grow to around USD 1.95 billion by 2030 with a compound annual growth rate (CAGR) of roughly 5.90% between 2023 and 2030. The report analyzes the global aquagenic pruritus treatment market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the aquagenic pruritus treatment industry.
Aquagenic pruritus is an extremely rare and uncommon medical condition in which patients suffer from intense irritation and itching when they come in contact with water. The temperature or source of water is irrelevant in this condition. The medical community does not have an answer to the exact source of the condition and hence is a significant lack of a definitive cure. However, the industry players along with medical professionals have managed to develop several therapies and treatments that can help patients of aquagenic pruritus deal with symptoms. This includes oral and topical medication along with phototherapy and other non-pharmacological treatments. As the research & development related to the condition and its possible cure has increased over the years, the aquagenic pruritus industry has managed to grow steadily. During the forecast period, the expansion outlook is expected to be positive.
Increasing prevalence of the condition to propel market growth
The global aquagenic pruritus treatment market is projected to grow owing to the increasing number of patients suffering from the condition. Although the medical issue is rare, the number of patients diagnosed with aquagenic pruritus has grown in the last few years. Currently, it is estimated to affect nearly 1% of the world’s population and is considered to be more common in females than males. It can also occur at any age. Researchers believe that the condition is triggered due to the activation of nerve fibers that are present in the skin as a reaction to contact with water. However, the exact mechanism is still unclear. The main symptom of the condition includes intense skin irritation or itching. This greatly impacts the quality of life of the patient.
Lack of a definitive cure to restrict market expansion
One of the major growth restraints in the global aquagenic pruritus industry is the lack of a definitive cure for the condition. Currently, the medical community has access to only treatments that allow patients to manage the symptoms but they cannot completely cure the disease. There is a significant lack of knowledge on what is the underlying cause of aquagenic pruritus making it difficult for the pharmaceutical developed to produce an accurate cure. Furthermore, the impact of the treatment therapy may depend from patient to patient leading to restricted growth in the industry.
Increasing investment toward the development of novel therapies to provide growth opportunities
The global aquagenic pruritus market players may benefit from the increasing investment toward the development of novel treatments and therapies that provide better results. For instance, drug developers along with the assistance of medical professionals are working on exploring the use of Janus Kinase (JAK) inhibitors that can block the action of the JAK enzymes which are known to play a crucial role in the immune system’s reaction to any inflammation.
Lack of wide-scale awareness to challenge market growth
The global aquagenic pruritus industry size is highly limited due to the lack of wide-scale awareness amongst the patient group about the condition. Most people, especially in rural areas, are not completely aware of the issue and may consider it as a simple reaction to contaminated water. The government and healthcare agencies need to amplify programs to educate the masses about the condition and possible treatment to ensure higher demand in the industry.
The global aquagenic pruritus treatment market is segmented based on distribution channel, treatment, route of administration, and region.
Based on distribution channel, the global market segments are retail pharmacy, hospital pharmacy, and online pharmacy. In 2022, the hospital pharmacy segment witnessed the highest growth followed by the retail pharmacy segment. The condition generally cannot be diagnosed without the assistance of expert professionals. The hospitals are more equipped in terms of diagnostic tools and human resources to diagnose the condition and provide effective treatment measures. In addition to this, some patients may require specialized care since the treatment for aquagenic pruritus does not have a standard protocol. As per the Centers for Medicare & Medicaid Services (CMS), the US government spent nearly USD 11 trillion on healthcare in 2019.
Based on treatment, the aquagenic pruritus industry divisions are transcutaneous electrical nerve stimulation (TENS), medication, phototherapies, and others.
Based on route of administration, the global market segments are topical, oral, parenteral, and others. The oral segment witnessed the highest growth in 2022 and may continue its dominance during the forecast period. Most professionals recommend taking antihistamines to curb the symptoms associated with the conditions and these medicines are generally taken orally with food or water. Another significant segmental growth is observed in the topical segment where doctors may recommend the use of baby oil or other natural supplements for pain relief. Skin itching may last up to 30 minutes or more during the episode.
Report Attributes | Report Details |
---|---|
Report Name | Aquagenic Pruritus Treatment Market Research Report |
Market Size in 2022 | USD 1.23 Billion |
Market Forecast in 2030 | USD 1.95 Billion |
Growth Rate | CAGR of 5.90% |
Number of Pages | 216 |
Key Companies Covered | Sun Pharmaceutical Industries Ltd., Pfizer, Inc., GlaxoSmithKline plc., Novartis International AG, Johnson & Johnson Services, Inc., Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Merck & Co., Inc., AstraZeneca plc., Mylan N.V., Allergan plc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Amgen Inc., F. Hoffmann-La Roche Ltd., Biogen Inc., Bayer AG, Lupin Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Perrigo Company plc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., and Taro Pharmaceutical Industries Ltd. |
Segments Covered | By Distribution Channel, By Treatment, By Route of Administration, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2023 - 2030 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America to witness the highest growth
The global aquagenic pruritus treatment market is projected to witness the highest growth in North America mainly due to the advanced healthcare and research infrastructure of the US and Canada. The government of the former country spends large amounts on public healthcare by undertaking various awareness campaigns and providing resources to research organizations. In addition to this, the presence of some of the key pharmaceutical players such as Pfizer, Johnson & Johnson, amongst many other corporations, works in the favor of the regional market. These companies invest large resources in research activities or well-established treatment processes for certain conditions as well as lesser-known diseases such as aquagenic pruritus. Asia-Pacific is projected to emerge as a significant revenue generator owing to the increasing investments in the regional pharmaceutical industries of India, China, Japan, and South Korea.
The global aquagenic pruritus treatment market is led by players like:
By Distribution Channel
By Treatment
By Route of Administration
FrequentlyAsked Questions
Aquagenic pruritus is an extremely rare and uncommon medical condition in which patients suffer from intense irritation and itching when they come in contact with water.
The global aquagenic pruritus treatment market is projected to grow owing to the increasing number of patients suffering from the condition.
According to study, the global aquagenic pruritus treatment market size was worth around 1.23 billion in 2022 and is projected to reach USD 1.95 billion by 2030.
The CAGR value of the aquagenic pruritus treatment market is expected to be around 5.90% during 2023-2030.
The global aquagenic pruritus treatment market is projected to witness the highest growth in North America mainly due to the advanced healthcare and research infrastructure of the US and Canada.
The global aquagenic pruritus treatment market is led by players like Sun Pharmaceutical Industries Ltd., Pfizer, Inc., GlaxoSmithKline plc., Novartis International AG, Johnson & Johnson Services, Inc., Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Merck & Co., Inc., AstraZeneca plc., Mylan N.V., Allergan plc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Amgen Inc., F. Hoffmann-La Roche Ltd., Biogen Inc., Bayer AG, Lupin Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Perrigo Company plc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., and Taro Pharmaceutical Industries Ltd.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed